TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Selling and Marketing Expense in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Selling and Marketing Expense history and growth rate from Q1 2010 to Q2 2024.
  • Teva Pharmaceutical Industries Ltd Selling and Marketing Expense for the quarter ending June 30, 2024 was $656M, a 8.79% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd Selling and Marketing Expense for the twelve months ending June 30, 2024 was $2.45B, a 9.62% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Selling and Marketing Expense for 2023 was $2.34B, a 3.14% increase from 2022.
  • Teva Pharmaceutical Industries Ltd annual Selling and Marketing Expense for 2022 was $2.27B, a 6.75% decline from 2021.
  • Teva Pharmaceutical Industries Ltd annual Selling and Marketing Expense for 2021 was $2.43B, a 2.76% decline from 2020.
Selling and Marketing Expense, Trailing 12 Months (USD)
Selling and Marketing Expense, Quarterly (USD)
Selling and Marketing Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $2.45B $656M +$53M +8.79% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $2.4B $608M +$62M +11.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $2.34B $611M +$63M +11.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 $2.27B $576M +$37M +6.87% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $2.24B $603M +$9M +1.52% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $2.23B $546M -$38M -6.51% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $2.27B $548M -$84M -13.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 $2.35B $539M -$58M -9.72% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $2.41B $594M -$21M -3.42% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $2.43B $584M -$1M -0.17% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $2.43B $632M -$51M -7.47% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $2.48B $597M -$8M -1.32% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $2.49B $615M +$18M +3.02% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 $2.47B $585M -$28M -4.57% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 $2.5B $683M -$22M -3.12% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 $2.52B $605M +$10M +1.68% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 $2.51B $597M -$69M -10.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 $2.58B $613M -$35M -5.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 $2.61B $705M -$92M -11.5% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 $2.71B $595M -$104M -14.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $2.81B $666M -$16M -2.35% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $2.83B $648M -$90M -12.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $2.92B $797M +$147M +22.6% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-10
Q3 2018 $2.77B $699M -$144M -17.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $2.91B $682M -$262M -27.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $3.18B $738M -$220M -23% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $3.4B $650M -$479M -42.4% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 $3.87B $843M -$97M -10.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $3.97B $944M -$8M -0.84% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $3.98B $958M +$119M +14.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $3.86B $1.13B +$213M +23.3% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 $3.65B $940M +$160M +20.5% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 $3.49B $952M +$92M +10.7% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 $3.4B $839M -$83M -9% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 $3.48B $916M -$90M -8.95% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 $3.57B $780M -$170M -17.9% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 $3.74B $860M -$61M -6.62% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 $3.8B $922M -$62M -6.3% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 $3.86B $1.01B -$126M -11.1% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 $3.99B $950M -$21M -2.16% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 $4.01B $921M -$61M -6.21% Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 $4.07B $984M -$11M -1.11% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 $4.08B $1.13B +$76M +7.2% Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 $4B $971M +$57M +6.24% Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 $3.95B $982M +$1M +0.1% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 $3.95B $995M +$67M +7.22% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 $3.88B $1.06B +$20M +1.93% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 $3.86B $914M +$108M +13.4% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 $3.75B $981M +$177M +22% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 $3.57B $928M +$96M +11.5% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 $3.48B $1.04B +$215M +26.2% Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 $3.26B $806M +$55M +7.32% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 $3.21B $804M +$160M +24.8% Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 $3.05B $832M +$80M +10.6% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 $2.97B $821M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 $751M Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 $644M Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 $752M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.